DVAX — Dynavax Technologies Share Price
0.000.00%
Last trade - 00:00- $1.47bn
- $969.36m
- $232.28m
- 65
- 19
- 48
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 39.82 | ||
| PEG Ratio (f) | 0.52 | ||
| EPS Growth (f) | 336.24% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.42 | ||
| Price to Tang. Book | 2.43 | ||
| Price to Free Cashflow | 28.39 | ||
| Price to Sales | 6.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.64% | ||
| Return on Equity | 1.56% | ||
| Operating Margin | -10.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 35.22 | 46.55 | 439.44 | 722.68 | 232.28 | 284.85 | 348.96 | 95.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +235.61 | n/a | n/a | +132.39 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Directors
- Scott Myers CHM (55)
- David Novack PRE (59)
- Ryan Spencer CEO (43)
- Kelly MacDonald CFO (37)
- John Slebir SVP
- Jeff Coon SVP
- Robert Janssen SVP (67)
- Dong Yu SVP
- Andrew Hack DRC (48)
- Elaine Sun DRC
- Francis Cano IND (77)
- Julie Eastland IND (56)
- Daniel Kisner IND (74)
- Brent MacGregor IND (57)
- Peter Paradiso IND (70)
- Peggy Phillips IND (67)
- Natale Ricciardi IND (72)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 6th, 2000
- Public Since
- February 19th, 2004
- No. of Shareholders
- 39
- No. of Employees
- 408
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 130,891,710
- Address
- 2100 Powell Street, Suite 720, EMERYVILLE, 94608
- Web
- https://www.dynavax.com/
- Phone
- +1 5108485100
- Contact
- Nicole Arndt
- Auditors
- Ernst & Young LLP
Upcoming Events for DVAX
Q3 2024 Dynavax Technologies Corp Earnings Release
Similar to DVAX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Dynavax Technologies share price?
As of Today at 20:23 UTC, shares in Dynavax Technologies are trading at $11.43. This share price information is delayed by 15 minutes.
How has the Dynavax Technologies share price performed this year?
Shares in Dynavax Technologies last closed at $11.43 and the price had moved by -12.08% over the past 365 days. In terms of relative price strength the Dynavax Technologies share price has underperformed the S&P500 Index by -30.04% over the past year.
What are the analyst and broker recommendations for Dynavax Technologies?
The overall consensus recommendation for Dynavax Technologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Dynavax Technologies dividend yield?
Dynavax Technologies does not currently pay a dividend.
Does Dynavax Technologies pay a dividend?
Dynavax Technologies does not currently pay a dividend.
When does Dynavax Technologies next pay dividends?
Dynavax Technologies does not currently pay a dividend.
How do I buy Dynavax Technologies shares?
To buy shares in Dynavax Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dynavax Technologies?
As of the previous close price of $11.43, shares in Dynavax Technologies had a market capitalisation of $1.50bn.
Where are Dynavax Technologies shares listed?
Here are the trading details for Dynavax Technologies:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: DVAX
What kind of share is Dynavax Technologies?
Based on an overall assessment of its quality, value and momentum Dynavax Technologies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dynavax Technologies share price forecast for 2024?
The analyst consensus target price for shares in Dynavax Technologies is $25.75. That is 125.28% above the last closing price of $11.43.
Analysts covering Dynavax Technologies currently have a consensus Earnings Per Share (EPS) forecast of $0.18 for the next financial year.
What is the trend in the Dynavax Technologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dynavax Technologies. Over the past six months, its share price has underperformed the S&P500 Index by -27.84%.
As of the last closing price of $11.43, shares in Dynavax Technologies were trading -12.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dynavax Technologies PE Ratio?
The Dynavax Technologies PE ratio based on its reported earnings over the past 12 months is 39.82. The shares last closed at $11.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dynavax Technologies?
Dynavax Technologies' management team is headed by:
- Scott Myers - CHM
- David Novack - PRE
- Ryan Spencer - CEO
- Kelly MacDonald - CFO
- John Slebir - SVP
- Jeff Coon - SVP
- Robert Janssen - SVP
- Dong Yu - SVP
- Andrew Hack - DRC
- Elaine Sun - DRC
- Francis Cano - IND
- Julie Eastland - IND
- Daniel Kisner - IND
- Brent MacGregor - IND
- Peter Paradiso - IND
- Peggy Phillips - IND
- Natale Ricciardi - IND